Identify clinical classifications and disease progressive biomarkers in metastatic, and triple negative breast cancer |
|
|
|
|
|
Analyze clinical trial data and mechanisms of action of available and developing therapeutics for metastatic breast cancer, as well as risk-benefit considerations in therapeutic selection |
|
|
|
|
|
Implement disease monitoring and patient screening strategies to develop personalized treatment plans to optimize patient outcomes in advanced metastatic breast cancer |
|
|
|
|
|